<DOC>
	<DOCNO>NCT02508870</DOCNO>
	<brief_summary>This non-randomized , open-label , Phase 1 study atezolizumab ( anti program death-ligand 1 [ anti-PD-L1 ] monoclonal antibody ) intermediate/high/very high-risk myelodysplastic syndrome ( MDS ) participant , evaluate International Prognostic Scoring System-Revised ( IPSS-R ) . Eligible participant either never receive treatment hypomethylating agent ( ) ( HMAs ) relapse refractory ( R/R ) prior HMA therapy . The primary objective study determine safety feasibility atezolizumab therapy participant population , include treatment combination azacitidine .</brief_summary>
	<brief_title>A Safety Pharmacology Study Atezolizumab Administered Alone Combination With Azacitidine Participants With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis MDS ( participant therapyrelated MDS eligible ) Eastern Cooperative Oncology Group ( ECOG ) performance status score less equal ( &lt; /= ) 2 Adequate endorgan function , determine laboratory test obtain within 28 day prior first dose study drug Willing able undergo pretreatment bone marrow biopsy subsequent ontreatment bone marrow biopsy Women postmenopausal surgically sterile must negative serum pregnancy test result within 28 day prior initiation study drug For woman childbearing potential men : agreement remain abstinent ( refrain heterosexual intercourse ) use highly effective contraceptive measure For participant Cohorts A B : Progression time initiation azacitidine decitabine treatment Failure achieve complete partial response hematological improvement least six 4week cycle azacitidine either four 4week four 6week cycle decitabine Relapse initial complete partial response hematological improvement six 4week cycle azacitidine either four 4week four 6week cycle decitabine administer within past 2 year Participants diagnosis hypoplastic MDS MDS secondary paroxysmal nocturnal hemoglobinuria ( PNH ) , aplastic anemia , another inherit bone marrow failure disorder Prior allogeneic stem cell transplant solid organ transplant Pregnant lactating , intend become pregnant study Investigational therapy within 28 day prior initiation study treatment Immunosuppressive therapy within 6 week Cycle 1 , Day 1 Prior treatment immune checkpoint blockade therapy ( anticytotoxic Tlymphocyteassociated protein 4 [ CTLA4 ] , antiprogrammed death1 [ PD1 ] antiPDL1 ) immune agonist ( anticluster differentiation [ CD ] 137 , antiCD40 , antiOX40 ) Any therapy serious medical condition , specify protocol , abnormality clinical laboratory test , investigator 's judgement , preclude participant 's safe participation completion study Left ventricular ejection fraction ( LVEF ) &lt; /= 40 percent ( % ) screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>